Serina Therapeutics, Inc. — Form S-1
Filed August 24, 2026 · analyzed by the Registration Agent
S-1
▼ Likely negative
significance 78/100
What the filing says
On August 21, 2026, Serina Therapeutics (clinical-stage biotech, market cap ~$21.8M) entered a Common Stock Purchase Agreement with Roth Principal Investments, LLC granting Serina the right to sell up to $25,000,000 of common stock over 36 months at VWAP-based prices (7–3% discount tiered). Up to 12,500,000 shares may be issued, representing ~33% dilution if fully drawn. Serina is not obligated to sell, and the timing/amount are entirely discretionary. No proceeds received yet; agreement effective August 21, 2026.
Why this rating
Material dilution ceiling ($25M ≈115% of $21.8M cap value) and near-term execution risk given going-concern doubt in 10-K. Significant relative to micro-cap size despite discretionary structure.
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.